Experimental Obesity Drug Seeks FDA Approval

Tools

By CBS-8 Reporter

The FDA is taking another look at an experimental obesity drug.

An advisory panel meets today and will consider the approval of Lorcaserin, which blocks appetite signals to the brain.

The FDA rejected the drug in 2010 because of its potential cancer and heart risk.

Today the drug company is presenting new data that it believes shows the drug is safe.
This content requires the latest Adobe Flash Player and a browser with JavaScript enabled. Click here for a free download of the latest Adobe Flash Player.

What's onFull Schedule

Hot Video From AP

AP Video